PT  - JOURNAL ARTICLE
AU  - Rawal, Harsh
AU  - Nguyen, Tung D
AU  - Igbinomwanhia, Efehi
AU  - Klein, Lloyd W
TI  - Clinical Effects of Physiologic Lesion Testing in Influencing Treatment Strategy for Multi-vessel Coronary Artery Disease
AID  - 10.1101/2023.05.17.23290067
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.17.23290067
4099  - http://medrxiv.org/content/early/2023/05/24/2023.05.17.23290067.short
4100  - http://medrxiv.org/content/early/2023/05/24/2023.05.17.23290067.full
AB  - Introduction Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) have become the standards for assessing physiological significance of intermediate-to-severe lesions on coronary angiography. However, the utilization of invasive physiology in patients with multi-vessel coronary artery disease (CAD) has not been definitively explored. The aim of this study is to examine how physiologic testing is applied to select treatment strategy in the clinic, and whether physiologic testing leads to differences in selection of treatment modality among patients presenting with two- and three-vessel CAD. The analysis identified how treatment strategy was decided based on FFR/iFR values in vessels selected clinically. Additionally, the differences in selection of treatment modality based on whether the vessel tested was the clinical target stenosis vessel was assessed.Methods In this series, 270 consecutive patients with angiographically determined multi-vessel disease who underwent FFR and/or iFR testing were included, and patients were classified initially based on their FFR/iFR results (normal or abnormal). Lesions were subsequently classified into target or non-target lesions based on clinical and non-invasive testing to identify if they were culprit lesions or not. Ordinal variables were analyzed using GraphPad Prism 8.4 (GraphPad Software). One-way ANOVA was used to determine if differences existed among the 3 subgroups prior to chi square testing. Chi-square goodness of fit test was used to determine if the treatment modality was chosen based on FFR/iFR values and lesion classification.Results FFR/iFR was abnormal in 51.9% of cases. Of the abnormal cases, 51.4% received coronary stenting (PCI) and 44.3% had bypass surgery (CABG). When the tested vessel was normal, CABG was least utilized. When the non-target vessel was tested, there was a substantial preference for PCI, however, when the target lesion was tested, all three treatments were used equally. In two-vessel CAD, the strategy depended on physiologic testing result of the target vessel. Medical therapy was preferred when the target vessel was normal, however, PCI was preferred if the target vessel was abnormal. In non-target vessel testing, PCI was preferred regardless of the physiologic testing result. The preferred treatment modality was substantially different in three-vessel CAD patients. Abnormal testing in target lesions was associated with significantly more CABG than medical therapy. PCI was preferred if the non-target vessel was tested. Furthermore, the incidence of tested lesions was significantly higher when located in the left anterior descending (LAD) when compared to other coronary arteries (e.g. left circumflex (LCX), right coronary artery (RCA)). In patients with two-vessel CAD, regardless of whether a target or non-target lesion was being tested, patients with LAD stenoses were more frequently treated by PCI.Conclusion The use of invasive physiologic testing in patients with multi-vessel CAD may alter the preferred treatment strategy. In clinical practice, this leads to a substantial increase in the use of PCI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no funding associated with the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the human research ethics committee of the Advocate Health Care Network (Ref. No. 1243433-1).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.